Percutaneous venous angioplasty in patients with multiple sclerosis and chronic cerebrospinal venous insufficiency


Venous percutaneous transluminal angioplasty ( vPTA ) in patients with multiple sclerosis ( MS ) and chronic cerebrospinal venous insufficiency ( CCSVI ) have shown contradictory results.
The aim of the study was to evaluate the efficacy of the procedure in a randomized wait list control study.

66 adults with neurologist-confirmed diagnosis of multiple sclerosis and sonographic diagnosis of CCSVI were allocated into vPTA-yes group ( n = 31 ) or vPTA-not group ( n = 35, control group ).
Venous percutaneous transluminal angioplasty was performed immediately 15 days after randomization in the PTA-yes group and 6 months later in the control group.
Evoked potentials ( EPs ), clinical-functional measures ( CFMs ), and upper limb kinematic measures ( ULKMs ) were measured at baseline ( T0 ) and six months after in both groups, just before the venous angioplasty in the vPTA-not group ( T1 ).

Comparing the vPTA-yes and vPTA-not group, the CFM-derived composite functional outcome showed 11 ( 37% ) versus 7 ( 20% ) improved, 1 ( 3% ) versus 3 ( 8% ) stable, 0 versus 7 ( 20% ) worsened, and 19 ( 61% ) versus 18 ( 51% ) mixed patients ( χ2 = 8.71, df = 3, P = 0.03 ).

Unadjusted and adjusted ( for baseline confounding variables ) odds ratio ( OR ) at 95% confidence interval were, respectively, 1.93 ( 1.3-2.8 ), P value 0.0007, and 1.85 ( 1.2-1.7 ), P value 0.002.

EP- and ULKM-derived composite functional outcome showed no significant difference between the two groups.

In conclusion, venous angioplasty can positively impact a few clinical-functional measures especially for the quality of life but achieving disability improvement is unlikely. ( Xagena )

Napoli V et al, Ann Vasc Surg 2019; Epub ahead of print

XagenaMedicine_2019



Indietro

Altri articoli

Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and...


The FDA ( Food and Drug Administration ) has cleared for marketing the ENROUTE Transcarotid Neuroprotection System ( ENROUTE TNS...


Silent infarction in the brain can be detected in around 34% of patients after carotid endarterectomy ( CEA ) and...


Early results of the SAMMPRIS ( Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis ) trial...


Clinical equipoise of carotid revascularization therapies remains controversial. Researchers sought to determine whether adverse outcomes after carotid endarterectomy ( CEA...


The European Medicines Agency ( EMA ), the Committee for Medicinal Products for Human Use ( CHMP ), and the...


The aim of a study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal...


Women suffer more disabling strokes than men and need to become better aware of their unique risk factors, according to...


The Resolute Integrity stent is a metal stent with the drug Zotarolimus contained in a thin coating on the stent’s...